SELLAS Life Sciences Group

SLS Lead: Phase 3 6 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-15

Catalyst timeline

GPS Galinpepimut-S BLA filing4Q 2026GPS Galinpepimut-S BLA filing, 4Q 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (9 active programs)

galinpepimut-S

GPS

Peptide Target: WT1, Wilms Tumor 1

Acute Myeloid Leukemia Phase 3 subcutaneous Memorial Sloan Kettering Cancer Center NCT01266083
Malignant Pleural Mesothelioma subcutaneous Memorial Sloan Kettering Cancer Center NCT01265433
Multiple Myeloma subcutaneous Memorial Sloan Kettering Cancer Center NCT01827137
Ovarian Cancer Phase 1/2 trial subcutaneous Merck NCT03761914

GPS+

Peptide Target: WT1

Undisclosed indication Preclinical 3D Medicines

tambiciclib

SLS009

Small Molecule Target: CDK9

Acute Myeloid Leukemia Phase 2 intravenous GenFleet
Peripheral T-Cell Lymphoma intravenous
Pediatric Acute Lymphoblastic Leukemia Preclinical
Pancreatic Ductal Adenocarcinoma Preclinical

Biotech Distilled coverage (6)

2026-08-12 UPDATE: SELLAS Life Sciences (SLS) - Three Months, Zero Events 🔒 Paid
2026-07-28 UPDATE: SELLAS Life Sciences (SLS) - The Stock Doubled, the Arbitration Died, and the Cash Grew 🔒 Paid
2026-05-12 UPDATE: SELLAS (SLS) - Two Events From the Bell 🔒 Paid
2026-03-22 UPDATE: SELLAS (SLS) - SEC Filings, Cash Runways, and a Peek at the Mechanism 🔒 Paid
2026-03-14 UPDATE: SELLAS (SLS) - Checking the Boxes on the SLS009 Pivot and Cash Runway 🔒 Paid
2025-12-29 SELLAS Life Sciences (SLS): Scientific Due Diligence for Lead and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.